Sonoma Pharmaceuticals SNOA 深 滬
已收盤 04-17 16:00:00 美东时间
2.30
+0.090
+4.07%
華盛通- 最 高2.335
- 今 開2.21
- 成交量 1.00万股
- 最 低 2.21
- 昨 收 2.21
- 總市值 398.04万
- 52周最高 6.9199
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 2.00
- 委 比 71.35%
- 總股本 173.06万
- 歷史最高 1484.64
- 量 比 0.56
- 振 幅 5.66%
- 歷史最低 1.75
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sonoma Pharmaceuticals Signs U.S. Microcyn Supply Agreement
Sonoma Pharmaceuticals ( ($SNOA) ) has provided an update. On April 8, 2026, So...
04-09 21:34
Sonoma Pharmaceuticals (SNOA) Jumps 16% After Hours On Burn Relief Hydrogel Launch In Walmart, CVS
Sonoma Pharmaceuticals jumps over 16% in after-hours trading following the U.S. retail launch of its burn relief hydrogel in CVS and Walmart stores.
03-27 14:35
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
Sonoma Pharmaceuticals Q3 EPS $(0.48) Misses $(0.31) Estimate, Sales $4.349M Beat $4.326M Estimate
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.31) by 54.84 percent. This is a 23.81 percent increase over losses of $(0.63) per
02-11 06:25
Sonoma Pharmaceuticals Q3 revenue rises 22%
Sonoma Pharmaceuticals Q3 revenue rises 22% Overview Healthcare product maker's fiscal Q3 revenue rose 22% yr/yr Net loss and EBITDAS loss decreased for fiscal Q3 compared to last year Company expanded distribution channels and strengthened leadership Outlook Sonoma Pharmaceuticals did not provide s
02-11 05:18
BRIEF-Sonoma Pharmaceuticals Q3 Net Income USD -600 Thousand
BRIEF-Sonoma Pharmaceuticals Q3 Net Income USD -600 Thousand Feb 10 (Reuters) - Sonoma Pharmaceuticals Q3 revenue USD 4.3 million. Q3 gross profit USD 1.6 million Q3 operating expenses USD 2.3 million
02-11 05:11
Sonoma Pharma Europe revenue up 31% to USD X in Q3
Sonoma Pharma Europe revenue up 31% to USD X in Q3 Sonoma Pharmaceuticals Inc. reported its financial results for the quarter ended December 31, 2025. The company highlighted a 31 percent increase in revenues from Europe, attributed to higher demand for its products. Revenues in Asia grew 38 percent
02-11 05:02
Sonoma Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director Vanessa Jacoby
Sonoma Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director Vanessa Jacoby Sonoma Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Vanessa Jacoby as the beneficial owner in her
02-10 06:00
Sonoma Pharmaceuticals Appoints Vanessa Jacoby to Board as Jay Birnbaum Retires
Sonoma Pharmaceuticals Appoints Vanessa Jacoby to Board as Jay Birnbaum Retires Sonoma Pharmaceuticals Inc. has announced that Dr. Jay Birnbaum retired from its Board of Directors effective January 28, 2026. The company appointed Vanessa Jacoby as a new independent director to replace Dr. Birnbaum.
01-29 05:02
Sonoma Pharmaceuticals to Exhibit at MEDICA in Düsseldorf
Sonoma Pharmaceuticals Inc. will exhibit at MEDICA 2025 in Düsseldorf, Germany, from November 17-20, 2025. The company will showcase its stabilized hypochlorous acid products for scar management, atop...
2025-11-07 05:01
